Thursday, November 02, 2017 8:29:08 AM
" I can't really go into more detail other than that until we have additional meetings and really flesh out what the protocol will look like, we intend to communicate that to the street as soon as we have a definitive plan in place just like we did with the Phase 2b/3 adaptive study design that we have with SYN-010.
Katherine Xu
So can you describe the interest level from industry, potential partners on this program?
Jeff Riley
Like I told you last quarter, we're talking to everybody Katherine at this point in time. I mean, there are discussions on for both drugs, from disparate companies. There's only a couple that are looking at both drugs together. The industry I think is beginning to look at licensing again. I think it's been pretty dry for the last two or three years from late stage Phase 2, Phase 3, the classic licensing deals. I think it's beginning to improve. Ken Frazier at Merck actually signaled that the other day that they were going to begin looking for things at Merck and I would guess that Pfizer said something similar as well in their earnings call. So I believe that the tide is going to turn for the big guys to start acquiring assets and filling their pipeline. So again, the only guidance I can give you is when we have a deal in hand and it becomes relevant, we'll announce it."
https://seekingalpha.com/article/4119328-synthetic-biologics-syn-ceo-jeff-riley-q3-2017-results-earnings-call-transcript?page=1
"Keith Markey
Couple of questions. I was just wondering if you might explain to us what you mean by -- what you're doing to solidify the clinical infrastructure for SYN-010. What does that involve?
Jeff Riley
It’s Jeff. Essentially, we’ve signaled the street that we're not going to spend the money to do that program ourselves at this time. It's just not something that we can do. We don't want to take the dilution in raising capital nor do we want to do that. So we're looking at building the infrastructure. We have great CROs over in Europe as well as here in the United States. We've talked to several. I think we have our prime lead CROs for both Europe as well as the United States and we're ready to go. So again, discussions on the business development side are, it’s highly likely that if we did get a deal, we will be the ones actually doing the work in collaboration with a CRO.
So that's what we meant by solidifying the clinical development plan. We're also beginning to obviously pivot toward more of a commercialization perspective as a company, because we're getting close to the end of this long road, 25th mile and a marathon if you will. So we are beginning to look at some of the commercialization components, the markets, how we would position the drug and we do have a head of marketing that is looking at all of these things at this point in time as well as manufacturing of both of the drugs. The manufacturing for SYN-010 is fairly bullet proof. I think we're ready to rock and roll and there is still some work to be done on ribaxamase to make sure that we have cGMP and CMC up and running for that biologic."
Recent TOVX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:10:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:07:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:01:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:00:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:15:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2023 11:10:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 10:05:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 10:06:35 AM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 08/16/2023 09:24:26 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/15/2023 01:53:41 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/14/2023 09:11:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 08:30:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 01:03:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 12:10:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2023 01:22:02 PM
- Another Biotech Stealing The Premarket Spotlight • AllPennyStocks.com • 06/28/2023 02:15:00 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM